中药复方YA3D3改善APP/PS1转基因小鼠阿尔茨海默病样病理及认知功能OA
Traditional Chinese Herbal Formula YA3D3 Ameliorates Alzheimer's Disease-Like Pathology and Cognitive Impairment in APP/PS1 Transgenic Mice
目的 探讨中药复方 YA3D3 对 APP/PS1 转基因小鼠认知障碍及脑内 β 淀粉样蛋白(Aβ)沉积的影响,及是否通过上调自噬关键基因 ATG14 发挥作用.方法 网络药理学预测 YA3D3 作用靶点;体外测定总抗氧化能力与羟自由基清除率.ATG14-短发夹 RNA慢病毒敲低BV2 小胶质细胞,用0.5 mg/mL YA3D3 水煎或发酵中药处理24 h,实时荧光定量PCR与 Western blot检测 ATG14 及下游 ATG16L1 表达.3 月龄 APP/PS1 雄性小鼠64 只随机分为 APP/PS1 模型组、盐酸多奈哌齐组、低剂量 YA3D3 水煎组、中剂量 YA3D3 水煎组、高剂量 YA3D3 水煎组、低剂量 YA3D3 发酵组、中剂量 YA3D3发酵组、高剂量 YA3D3 发酵组8 组,给药方式采取自由饮用,连续90 d;正常对照组为 C57BL/6 小鼠.Morris 水迷宫评估空间学习与记忆,免疫荧光测定脑组织 Aβ 沉积,实时荧光定量 PCR检测脑组织自噬相关基因表达.结果 网络药理学显示 YA3D3 显著富集于自噬、磷脂酰肌醇3-激酶/蛋白激酶 B 等通路.体外实验提示 YA3D3 发酵组抗氧化活性显著高于YA3D3 水煎组(P<0.001).细胞模型中,YA3D3 水煎组与发酵组均可逆转 ATG14 敲低引起的 ATG14 与 ATG16L1 下调,且YA3D3 发酵组效果更强(P=0.003).动物实验显示,与 APP/PS1 模型组相比,各 YA3D3 组逃避潜伏期缩短、原平台穿越次数增加(P 均<0.05),脑组织 Aβ 荧光强度降低(P 均<0.001);高剂量 YA3D3 发酵组疗效与盐酸多奈哌齐组相当.实时荧光定量 PCR证实 YA3D3 上调脑内 ATG14 并调控下游自噬基因表达(P 均<0.05).结论 中药复方 YA3D3 可能与上调 ATG14 自噬基因表达相关,进而减缓 Aβ 沉积,改善 APP/PS1 小鼠认知功能障碍,为 AD干预提供潜在中药候选方案.需指出的是,本研究尚未在体内直接验证 ATG14 的必需性,YA3D3 的体内疗效与 ATG14 上调的因果关系仍需进一步确认.本研究仅验证自噬相关分子的表达调控,尚未证实自噬通量增强.
Objective To evaluate the effects of the traditional Chinese herbal formula YA3D3 on cog-nitive impairment and cerebral β-amyloid(Aβ)deposition in APP/PS1 transgenic mice and to determine whether these effects are mediated by up-regulation of the autophagy-related gene 14(ATG14).Methods Network phar-macology was employed to predict YA3D3 targets.Total antioxidant capacity and hydroxyl free radical scavenging activity were measured in vitro.BV2 microglial cells were infected with short hairpin RNA(shRNA)lentivirus targeting ATG14(designated as sh-ATG14)and then treated with 0.5 mg/mL of either water-extract(YA3D3-HF)or fermented(YA3D3-MHF)preparation for 24 h.The expression levels of ATG14 and downstream ATG16L1 were assessed by qPCR and Western blot.Sixty-four 3-month-old male APP/PS1 mice were randomly allocated to eight groups(n=8):APP/PS1 model,donepezil,low-,medium-,and high-dose YA3D3-HF,and low-,medium-,and high-dose YA3D3-MHF.All the drugs were administered ad libitum in drinking water for 90 days.Spatial learning and memory were evaluated through the Morris water maze.Cerebral Aβ deposition was quantified by immunofluorescence.Autophagy-related gene expression in the brain tissue was analyzed by qPCR.Results Network pharmacology indicated significant enrichment of YA3D3 targets in autophagy and phosphati-dylinositol 3-kinase/protein kinase B signaling pathways.YA3D3-MHF showed stronger antioxidant activity than YA3D3-HF in vitro(P<0.001).In BV2 cells,both preparations reversed ATG14 knock-down-induced down-regulation in the expression of ATG14 and ATG16L1,with YA3D3-MHF being more potent(P=0.003).The animal experiment showed that all the YA3D3 groups exhibited shorter escape latency and more platform crossings than the APP/PS1 model group(all P<0.05),along with reduced Aβ fluorescence intensity(all P<0.001).The efficacy of high-dose YA3D3-MHF was similar to that of donepezil.qPCR confirmed that YA3D3 up-regulated the expression of ATG14 and modulated the expression of downstream autophagy-related genes in the brain tissue(all P<0.05).Conclusions The traditional Chinese herbal formula YA3D3 may up-regulate the expression of ATG14 to slow down Aβ deposition and ameliorate cognitive impairment in APP/PS1 mice,serving as a potential candidate for Alzheimer's disease intervention.It should be noted that this study has not directly verified the necessity of ATG14 in vivo,and the causal relationship between the in vivo therapeutic efficacy of YA3D3 and the up-regula-tion of ATG14 requires further confirmation.In addition,this study only verifies the expression regulation of auto-phagy-related molecules and does not confirm the enhancement of autophagy flux.
杨甜;马佳蕊;梁厶爻;张悦萌;郭玲;栗午娟;吕玉红
延安大学延安医学院延安市微生物药物创新及转化重点实验室,陕西 延安 716000延安大学延安医学院延安市微生物药物创新及转化重点实验室,陕西 延安 716000延安大学延安医学院延安市微生物药物创新及转化重点实验室,陕西 延安 716000咸阳市第一人民医院病理科,陕西 咸阳 712000咸阳市第一人民医院病理科,陕西 咸阳 712000西安医学高等专科学校医学技术学院康复教研室,西安 710309延安大学延安医学院延安市微生物药物创新及转化重点实验室,陕西 延安 716000
医药卫生
阿尔茨海默病中药组方ATG14β淀粉样蛋白微生物发酵
Alzheimer's diseasetraditional Chinese herbal formulaATG14β-amyloid peptidemicrobial fermentation
《中国医学科学院学报》 2026 (4)
618-630,13
咸阳市科技局项目(L2025-ZDYF-ZYY-019)、延安市科技局项目(2024-SFGG-201)、大学生创新创业训练计划项目(202410719056)和延安大学研究项目计划(2023KXJ-012、2023CGZH-001)
评论